Target intelligence / Profile preview

Lymphocyte function-associated antigen 3 (LFA-3) – Cluster of differentiation 2 (CD2) complex (LFA-3 – CD2 complex)

Target
LFA-3 – CD2 complex
Molecular classification
Receptor (UniProt: P06729), Cell adhesion molecule (UniProt: P19235), Costimulatory molecule (PubMed: 1633953), Other (Immunoglobulin superfamily) (UniProt: P19235)
01

Overview

The Lymphocyte function-associated antigen 3 (LFA-3) – Cluster of differentiation 2 (CD2) complex is a critical mediator of the immune response, formed by the interaction between LFA-3 (also known as CD58) and its receptor, CD2 (UniProt: P19235, P06729). LFA-3 is widely expressed on the surface of antigen-presenting cells, endothelial cells, and epithelial cells, while CD2 is primarily found on T lymphocytes and natural killer (NK) cells (PubMed: 10438934). This interaction facilitates stable cell-cell adhesion and provides essential costimulatory signals that lower the threshold for T cell receptor (TCR) activation, promoting T cell proliferation and cytokine production (PubMed: 1633953). In autoimmune and inflammatory conditions, such as chronic plaque psoriasis, this pathway is overactive, leading to the sustained activation of memory-effector T cells (StatPearls: NBK548582). Therapeutic targeting of this complex, most notably with the fusion protein alefacept, aims to disrupt this costimulatory signal and selectively deplete the pathogenic memory T cell population (DrugBank: DB00028). By binding to CD2, these therapies can effectively reduce inflammatory symptoms while maintaining a degree of overall immune competence compared to broader immunosuppressants.

Other names
CD58-CD2 complexLFA3-CD2 interactionCD58-CD2 adhesion pathwayLymphocyte function-associated antigen 3 – Cluster of differentiation 2 interaction
02

Mechanism of action

Alefacept, a fusion protein consisting of the extracellular CD2-binding portion of LFA-3 linked to the Fc portion of human IgG1, binds to CD2 on T cells (DrugBank: DB00028). This action blocks the interaction between LFA-3 and CD2, thereby inhibiting T cell activation and proliferation. Additionally, the Fc portion of the drug interacts with FcγRIII (CD16) on NK cells to induce apoptosis of memory-effector T cells (CD45RO+), which are the primary drivers of chronic plaque psoriasis (PubMed: 12648212).

03

Biological functions

Immune response (UniProt: P06729)Signal transduction (UniProt: P06729)Cell-cell adhesion (UniProt: P19235)T cell activation (PubMed: 1633953)Apoptosis (PubMed: 12648212)
04

Disease associations

Inflammation (StatPearls: NBK548582)Psoriasis (StatPearls: NBK548582)Graft-versus-host disease (PubMed: 15105686)Other (Cutaneous T-cell lymphoma) (PubMed: 11511309)
05

Safety considerations

Dose-dependent lymphopenia (FDA Label: Amevive)Increased risk of opportunistic infections (PubMed: 15507119)Requirement for weekly CD4+ T cell monitoring (FDA Label: Amevive)Potential for malignancy (PubMed: 15507119)
06

Interacting drugs

Alefacept

1 more in the full profile.

07

Biomarkers

CD4+ T cell count (FDA Label: Amevive)CD8+ T cell count (PubMed: 12165500)CD45RO+ memory T cell levels (PubMed: 12165500)

Beyond the preview

Go deeper on Lymphocyte function-associated antigen 3 (LFA-3) – Cluster of differentiation 2 (CD2) complex (LFA-3 – CD2 complex).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lymphocyte function-associated antigen 3 (LFA-3) – Cluster of differentiation 2 (CD2) complex (LFA-3 – CD2 complex).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call